Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 14.85 and traded as low as GBX 9.51. Scancell shares last traded at GBX 9.60, with a volume of 1,769,087 shares traded.
Scancell Stock Up 1.1%
The company has a market cap of £99.63 million, a P/E ratio of -17.45 and a beta of 0.69. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The business’s 50 day moving average is GBX 14.09 and its 200 day moving average is GBX 14.82.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
